Search clinical trials for: hematologic response

Total 28883 results

King Abdullah International Medical Research Center
Novartis

Terminated

Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy (NISRI)

Myeloid Leukemia, Chronic

Saudi Arabia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Leukemia, Myeloid, Chronic

Israel
Novartis Pharmaceuticals

Completed

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

Canada
Singapore General Hospital

Completed

Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy

Chronic Myeloid Leukemia

Singapore
H. Lee Moffitt Cancer Center and Research Institute

Completed

Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant (PCV13)

Multiple Myeloma

United States
Centre Hospitalier Universitaire de Nīmes

Withdrawn

Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms (abl LMC)

Leukemia, Myeloid, Chronic-Phase

France
Kansas State University
United States Department of Agriculture Foreign Agricultural Service

Completed

Multiple Daily Condensed Tannin Supplementation and Iron Bioavailability: The Tannin Dose Response Trial

Iron-deficiency | Iron Deficiency Anemia

United States
University of Arkansas

Withdrawn

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Multiple Myeloma

United States
Novo Nordisk A/S

Completed

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Healthy | Congenital Bleeding Disorder

United States
Celgene

Terminated

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

Multiple Myeloma

China
University of Michigan Rogel Cancer Center

Terminated

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

CHRONIC MYELOGENOUS LEUKEMIA

Canada, Australia, Spain, Argentina, France, Brazil
Hoffmann-La Roche

Terminated

A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B

Anemia

Venezuela
Sorveglianza Epidemiologica Infezioni Fungine Emopatie...

Completed

Fungemia in Hematologic Malignancies

Lymphoma | Multiple Myeloma | Acute Leukemia | Chronic Leukemia

Italy
National Institute of Blood and Marrow Transplant...
Novartis

Unknown

Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

Immune Thrombocytopenic Purpura (ITP)

Pakistan
Sheba Medical Center

Withdrawn

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia

Israel
MEI Pharma, Inc.

Completed

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (OVATURE)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Spain, Belgium, United Kingdom, Australia, Italy, Poland
Children's Healthcare of Atlanta

Completed

Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children (TAMOF)

Septic Shock | Thrombocytopenia | Multiple Organ Failure

United States
Boston VA Research Institute, Inc.
Dana-Farber Cancer Institute

Completed

Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias

Plasma Cell Disorder

United States
University of Oxford
British Heart Foundation; National Institute for Health Research, United Kingdom

Completed

Iron Status and Hypoxic Pulmonary Vascular Responses

Pulmonary Arterial Hypertension | Iron Deficiency | Lung Hypoxia

United Kingdom
Shandong University
West China Hospital; Jinan Military General Hospital; Shandong University of... and other collaborators

Completed

Autoantibody Specificity and Response to IVIG in ITP

Immune Thrombocytopenia (ITP)

China
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (MACS0911)

Philadelphia Chromosome Positive | Chronic Myelogenous Leukemia in Chronic Phase

Japan
University of Arkansas

Withdrawn

UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

Multiple Myeloma

United States
Hareth Nahi

Completed

Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line

Multiple Myeloma

Sweden
Novartis Pharmaceuticals

Terminated

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Primary Myelofibrosis

Spain, Germany, Italy
Watson Pharmaceuticals

Completed

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) (DRIVE)

Anemia, Iron-Deficiency | Hemodialysis | Kidney Failure, Chronic

United States
University Hospital, Lille
Celgene Corporation

Completed

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) (IFM2010-02)

Multiple Myeloma

France
Novartis Pharmaceuticals

Completed

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib (LASOR)

Chronic Myelogenous Leukemia

China, Argentina, Russian Federation, Germany, Guatemala, Panama, Colombia, Mexico, Brazil, India, Poland, Venezuela
Chang Gung Memorial Hospital

Completed

C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT (ACTMM)

Multiple Myeloma

Taiwan
University Hospital, Lille
Celgene Corporation

Completed

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma (IFM2009-02)

Multiple Myeloma

France
Kanto CML Study Group
Epidemiological and Clinical Research Information Network

Completed

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib (CMR-CML)

Chronic Myeloid Leukemia

Japan
Assistance Publique Hopitaux De Marseille

Completed

Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients

HIV-HCV Co-infected Patients

France
Sir Ganga Ram Hospital

Completed

Latent Iron Deficiency at Birth Influences Auditory Neural Maturation in Late Preterm and Term Infants

Latent Iron Deficiency at Birth
Mayo Clinic
rEVO Biologics

Terminated

Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

Thrombophilia Due to Acquired Antithrombin III Deficiency

United States
University of Cologne

Completed

Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells (MoxiProph)

Multiple Myeloma | Hodgkin Disease | Bacteremia | Non-Hodgkin Lymphoma

Germany
Jinling Hospital, China

Unknown

rhTPO in Critical Patients With Thrombocytopenia

Sepsis | Thrombocytopenia

China
Prothya Biosolutions

Completed

Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response (Subklasse)

Infections | IgG Deficiency

Netherlands
M.D. Anderson Cancer Center

Completed

Clofarabine in Chronic Lymphocytic Leukemia

Lymphoproliferative Disorders | Leukemia | Hematologic Neoplasms | Leukemia, Lymphocytic, Chronic

United States
Sheba Medical Center

Unknown

Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders

Severe Hemophilia

Israel
Università degli Studi di Brescia

Completed

Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy (INTERIM0407)

Chronic Myeloid Leukemia

Italy
University of Arkansas

Withdrawn

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Multiple Myeloma

United States
Mayo Clinic

Completed

Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients

Eosinophilic Esophagitis

United States
Australasian Leukaemia and Lymphoma Group
Merck Sharp & Dohme LLC; Novartis Pharmaceuticals

Unknown

Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (PInNACLe)

Chronic Myeloid Leukaemia

Australia
Janssen Korea, Ltd., Korea

Completed

Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients

Neutropenia | Fever | Hematological Malignancies
Mooselmokadem

Unknown

Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate

Neonatal Sepsis

Egypt
Janssen-Cilag Ltd.,Thailand
Mahidol University

Terminated

An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy

Anemia - Cancer Related

Thailand
University of Erlangen-Nürnberg Medical School
German Research Foundation; University Hospital, Essen; Wuerzburg University... and other collaborators

Unknown

Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination (B-cell therapy)

Acute Myeloid Leukemia | Multiple Myeloma | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Aplastic Anemia | Non Hodgkin's Lymphoma | Hodgkin's Disease

Germany
Ostfold Hospital Trust
Oslo University Hospital; South-Eastern Regional Health Authority

Completed

Rituximab as Second Line Treatment for ITP

Immune Thrombocytopenia (ITP)

Norway
Cornell University
University of Rochester

Completed

Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn

Anemia

United States
Nottingham University Hospitals NHS Trust

Completed

Intravenous Iron: Measuring Response in Anemic Surgical Patients

Anemia | Colorectal Neoplasm

United Kingdom

3

Subscribe